+5 | The top 5 medtech stories for August 24, 2016

Say hello to MassDevice +5, a bite-sized view of the top five medtech stories of the day. This feature of’s coverage highlights our 5 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry. Get this in your inbox everyday by subscribing to our newsletters.   5. Syneron Candela dumps Olympic swimmer Ryan Lochte Syneron Candela this week severed its ties with Olympic swimmer Ryan Lochte, who was a spokesman for the aesthetic device company’s Gentle Hair Removal brand. “We hold our employees to high standards, and we expect the same of our business partners,” Yokneam, Israel-based Syneron Candela said. “We wish Ryan well on his future endeavors and thank him for the time he spent supporting our brand.” Read more 4. SRS Medical launches Spanner prostate device study SRS Medical Systems said today it enrolled the 1st patients in an FDA investigational device exemption study as it seeks to expand the indications for its Spanner temporary prostatic stent. The Spanner device consists of a pair of anchors and a silicone tube and is designed to reduce resistance in the bladder neck and prostatic urethra without stenting the external sphincter, SRS said. It’s blind, anesthesia-free implantation procedure is similar to that for a Foley catheter, according to the company. Read more 3. Senators press ...
Source: Mass Device - Category: Medical Equipment Authors: Tags: News Well Plus 5 Source Type: news

Related Links:

Conclusion: Radical cystectomy is a standard treatment for muscle invasive bladder cancer. Oncologic outcomes of radical cystectomy is generally favorable, however, surgery alone had no more potential to prolong survival of patients with invasive cancer, multimodal treatment approaches might need. PMID: 29911376 [PubMed - in process]
Source: Journal of the Medical Association of Thailand = Chotmaihet thangphaet - Category: General Medicine Tags: J Med Assoc Thai Source Type: research
RAANANA, Israel (Reuters) - Israel's UroGen Pharma plans to begin a mid-stage trial of its treatment for bladder cancer patients in August, after positive interim results last month from an advanced trial of a treatment for upper urinary tract cancer.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news
ConclusionsAlthough intravesical ALS treatment has similar antiproliferative effects like BCG, ALS  + BCG combined treatment led to a best histopathologic and apoptotic response. Consequently, BCG combined with Aurora-A inhibition may provide a new intravesical treatment modality in the prevention of bladder carcinogenesis.
Source: International Urology and Nephrology - Category: Urology & Nephrology Source Type: research
In this study, the potential for SWNHs to serve as nanotheranostic vehicles is demonstrated through simultaneous delivery of the chemotherapeutic cisplatin from SWNH cone interiors and imaging of the nanoparticle transport to tumor cells using conjugated quantum dots (QDs). Following the formation of cisplatin-modified SWNH-QD (SWNH-QD + cis) hybrids, their characterization by scanning and transmission electron microscopy (STEM, TEM), energy dispersive spectroscopy (EDS), and dynamic light scattering (DLS) were performed to characterize the composite nanoparticles. Drug release profiles and 50% inhibitory concent...
Source: Carbon - Category: Materials Science Source Type: research
PHLPP2 stabilization by p27 mediates its inhibition of bladder cancer invasion by promoting autophagic degradation of MMP2 protein, Published online: 21 June 2018; doi:10.1038/s41388-018-0374-1PHLPP2 stabilization by p27 mediates its inhibition of bladder cancer invasion by promoting autophagic degradation of MMP2 protein
Source: Oncogene - Category: Cancer & Oncology Authors: Source Type: research
CONCLUSIONS: Our results pointed out that lncRNA DUXAP8 was overexpressed in bladder cancer tissues, which can promote the progression of bladder cancer through inhibiting PTEN. PMID: 29917188 [PubMed - in process]
Source: European Review for Medical and Pharmacological Sciences - Category: Drugs & Pharmacology Tags: Eur Rev Med Pharmacol Sci Source Type: research
This study aimed to explore the mechanism of paclitaxel on the inhibition of bladder cancer cell proliferation by applying paclitaxel combined with miR-448 on bladder cancer cells. MATERIALS AND METHODS: Bladder cancer EJ cells were divided into 5 groups, including control group, paclitaxel group, negative control (NC) group, microRNA-448 (miR-448) mimic group, and paclitaxel combined with miR-448 mimic group. Cell apoptosis was tested by flow cytometry. Cell proliferation was determined by cell counting kit 8 (CCK8) assay. The regulation of miR-448 on B cell lymphoma 2 (Bcl-2) gene was assessed by dual luciferase repo...
Source: European Review for Medical and Pharmacological Sciences - Category: Drugs & Pharmacology Tags: Eur Rev Med Pharmacol Sci Source Type: research
Conditions:   Bladder Cancer;   Urine Marking;   Diagnoses Disease Intervention:   Diagnostic Test: Genomic Imprinting Testing Sponsors:   Changhai Hospital;   LiSen imprinting diagnostic (LSID) Company Recruiting
Source: - Category: Research Source Type: clinical trials
WEDNESDAY, June 20, 2018 -- Compared with males, females who undergo radical cystectomy for bladder cancer have worse disease-free, cancer-specific, and overall survival, according to a review published in the July issue of The Journal of...
Source: - Pharma News - Category: Pharmaceuticals Source Type: news
In conclusion, the present study demonstrated that LASS2 inhibits bladder cancer invasion and chemoresistance through regulation of ERK-Drp1 induced mitochondrial dynamics.
Source: Journal of Cancer - Category: Cancer & Oncology Authors: Tags: Research Paper Source Type: research
More News: Anesthesia | Anesthesiology | Bladder Cancer | Cancer | Cancer & Oncology | Cancer Therapy | Eyes | Liver | Medical Devices | Middle East Health | Study | Urology & Nephrology